目的:建立首批贝那鲁肽国家标准品。方法:采用质谱法、N-末端氨基酸序列测定、氨基酸比值法以及质量肽图法进行结构确证;采用HPLC法测定纯度;采用质量平衡法对原料药A(大规格样品)进行含量赋值,然后以原料药A为对照品,采用HPLC外标法对原料药B(待标品)的含量进行标定;采用体外细胞培养法对原料药B(待标品)进行效价测定。并对原料药B(待标品)稳定性及均一性进行了考察。结果:确证了贝那鲁肽的结构,并确定了首批贝那鲁肽国家标准品的含量为0.932 mg·支-1,生物效价为1.0×104 U·支-1。原料药B(待标品)分别在4 ℃及25 ℃,RH 80%条件下放置10 d,纯度无明显下降,光照10 d纯度明显下降。15支原料药B(待标品)含量测定结果的RSD为0.86%,均一性良好。结论:首批贝那鲁肽国家标准品可作为贝那鲁肽及相关制剂HPLC法鉴别、含量测定及生物活性测定用标准品。
丁晓丽, 吕萍, 蔡永清, 段徐华, 王绿音, 陈莹, 徐可铮, 李晶,张伟, 胡馨月, 李懿, 孙悦, 张慧, 梁成罡
. 首批贝那鲁肽国家标准品的研制*[J]. 药物分析杂志, 2022
, 42(1)
: 78
-85
.
DOI: 10.16155/j.0254-1793.2022.01.09
Objective: To establish the first national reference standard of beinaglutide. Methods: TOF-MS, N-terminal sequence determination, ratio coefficient of amino acid, peptide mapping were used to confirm the structure of beinaglutide. The purity was determined by HPLC. The content of active pharmaceutical ingredients A(API,sample of large size) was determined by mass balance method. Using API A as reference substance, the content of API B(candidate standard) was determined by HPLC external standard method. The potency of API B was determined by cell culture in vitro. Andthe stability and uniformity of API B(the candidate preparation) were investigated. Results: The structure of the beinaglutide was confirmed, the content of the first beinaglutide natio-nal reference standard was assigned as 0.932 mg per ampoule and the potency was 1.0×104 U per ampoule. The purity of API B(candidate preparation) was not significantly decreased when it was placed at 4 ℃ or 25 ℃, RH 80% for 10 d, and the purity was significantly decreased when it was exposed to light for 10 d. RSD of 15 API B(candidate standard) was 0.86%, showing good homogeneity. Conclusion: The first batch of national standard beinaglutide could be used for HPLC identification, content determination and biological activity determination of benalutide and related preparations of beinaglutide.
[1] DRUCKER DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J].Cell Metab, 2018, 27(4): 740
[2] 王颖颖, 汤立达. 胰高血糖素样肽-1受体激动剂药理作用的研究进展[J].现代药物与临床, 2020, 35(1): 179
WANG YY, TANG LD. Research progress on pharmacological action of glucagon-like peptide-1 receptor agonists[J].Drugs Clin, 2020, 35(1): 179
[3] 王军志. 生物技术药物研究开发与质量控制[M].北京: 科学出版社, 2018: 736
WANG JZ. Research, Development and Quality Control of Biopharmaceuticals[M].Beijing: Science Press, 2018: 736
[4] CHEANG JY, MOYLE PM. Glucagon-like peptide-1 (GLP-1)-based therapeutics: current status and future opportunities beyond type 2 diabetes[J].Chem Med Chem, 2018, 13(7):662
[5] M#xDC;LLER TD, FINAN B, BLOOM SR, et al. Glucagon-like peptide 1 (GLP-1) [J].Mol Metab, 2019, 12(30): 72
[6] NOLEN-DOERR E, STOCKMAN MC, RIZO I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity[J].Curr Obes Rep, 2019, 8(3): 284
[7] 田沛霖, 张国林. 重组人胰岛素原料药N末端氨基酸序列的测定[J].中国合理用药探索, 2020, 12(12): 89
TIAN PL, ZHANG GL. Determination of the N-terminal amino acid sequence in the API of recombinant human insulin[J].Chin J Rational Drug Use, 2020, 12(12): 89
[8] 孙瑞祥, 罗兰, 迟浩, 等. “自顶向下”的蛋白质组学—蛋白质变体的规模化鉴定[J].生物化学与生物物理进展, 2015, 42(2): 101
SUN RX, LUO L, CHI H, et al. Top-down proteomics-the large-scale proteoform identification[J].Progress Biochem Biophy, 2015, 42(2): 101
[9] CUI W, ROHRS HW, GROSS ML. Top-down mass spectrometry: recent developments, applications and perspectives[J].Analyst, 2011, 136(19): 3854
[10] 中华人民共和国药典2020年版. 四部[S].2020:114, 121, 95, 206
ChP 2020. Vol Ⅳ[S].2020: 114, 121, 95, 206
[11] 韩永志. 标准物质的定值[J].化学分析计量, 2001, 10(5): 38
HANG YZ. Certification of certified reference materials[J].Chem Anal Meterage, 2001, 10(5): 38
[12] 曾文珊, 廖海明. 重组人甲状旁腺激素1-34的氨基酸组成分析[J].药物生物技术, 2003, 10(2): 108
ZENG WS, LIAO HM. Analysis of the amino acid composition of recombinant human parathyroid hormone 1-34[J].Pharm Biotechnol, 2003, 10(2): 108
[13] 许有诚, 费善芬. 口服水解蛋白液中氨基酸的测定[J].中国医药, 2003, 2(6): 40
XU YC, FEI SF. Determination of amino acids in oral protein hydrolysate[J].China Med, 2003, (6): 40
[14] 李克坚, 梁成罡, 杨勇, 等. 重组促胰岛素分泌素生物学活性测定方法的研究[J].药物分析杂志, 2006, 26(12): 1691
LI KJ, LIANG CG, YANG Y, et al. Study methods of biological activity determination of recombinant human extendin-4[J].Chin J Pharm Anal, 2006, 26(12): 1691
[15] 蔡永青, 陈霞, 梁成罡, 等. GLP-1受体激动剂生物学活性测定方法: 中国, 200910265928.1[P].2010-08-11
CAI YQ, CHEN X, LIANG CG, et al. Study Methods of Biological Activity Determination of GLP-1 Receptor Agonist: China, 200910265928.1[P].2010-08-11
